Mesoblast (MESO) Interest Expenses (2015 - 2025)
Mesoblast recorded quarterly Interest Expenses of $10.8 million in Q2 2025, up 4.56% quarter-over-quarter from $10.3 million in Q2 2024, and up 4.56% year-over-year from $10.3 million in Q2 2024.
Mesoblast's Interest Expenses history runs 11 years deep, the most recent figure standing at $10.8 million for Q2 2025.
- In Q2 2025, Interest Expenses rose 4.56% year-over-year to $10.8 million; the TTM figure through Dec 2025 stood at $21.1 million (changed 0.5% YoY), while the FY2025 annual figure was $23.0 million, changed 0.18% from the prior year.
- Interest Expenses came in at $10.8 million for Q2 2025 at Mesoblast, up from $10.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $15.7 million in Q1 2023 to a low of -$4.9 million in Q4 2022.
- A 5-year average of $4.8 million and a median of $6.1 million in 2021 frame the typical range for Interest Expenses.
- On a YoY basis, Interest Expenses climbed as much as 2323.82% in 2021 and fell as far as 179.14% in 2021.
- Mesoblast's Interest Expenses stood at -$4.1 million in 2021, then declined by 20.7% to -$4.9 million in 2022, then surged by 317.88% to $10.7 million in 2023, then fell by 3.43% to $10.3 million in 2024, then advanced by 4.56% to $10.8 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $10.8 million, $10.3 million, and $10.7 million for Q2 2025, Q2 2024, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 10.79 Mn |
| Jun 30, 2025 | 10.79 Mn |
| Jun 30, 2024 | 10.32 Mn |
| Jun 30, 2024 | 10.32 Mn |
| Jun 30, 2023 | 10.69 Mn |
| Jun 30, 2023 | 10.69 Mn |
| Mar 31, 2023 | 15.67 Mn |
| Mar 31, 2023 | 15.67 Mn |
| Dec 31, 2022 | -4.90 Mn |
| Dec 31, 2022 | -4.90 Mn |
| Sep 30, 2022 | 4.55 Mn |
| Sep 30, 2022 | 4.55 Mn |
| Jun 30, 2022 | 12.94 Mn |
| Jun 30, 2022 | 12.94 Mn |
| Mar 31, 2022 | -4.30 Mn |
| Mar 31, 2022 | -4.30 Mn |
| Dec 31, 2021 | -4.06 Mn |
| Dec 31, 2021 | -4.06 Mn |
| Sep 30, 2021 | -4.14 Mn |
| Sep 30, 2021 | -4.14 Mn |
| Jun 30, 2021 | 2.53 Mn |
| Jun 30, 2021 | 2.53 Mn |
| Mar 31, 2021 | 7.73 Mn |
| Mar 31, 2021 | 7.73 Mn |
| Dec 31, 2020 | 5.13 Mn |
| Dec 31, 2020 | 5.13 Mn |
| Sep 30, 2020 | -2.90 Mn |
| Sep 30, 2020 | -2.90 Mn |
| Jun 30, 2020 | 6.76 Mn |
| Jun 30, 2020 | 6.76 Mn |
| Mar 31, 2020 | 319,000.00 |
| Mar 31, 2020 | 319,000.00 |
| Dec 31, 2019 | 4.34 Mn |
| Dec 31, 2019 | 4.34 Mn |
| Sep 30, 2019 | -3.58 Mn |
| Sep 30, 2019 | -3.58 Mn |
| Jun 30, 2019 | 5.21 Mn |
| Jun 30, 2019 | 5.21 Mn |
| Mar 31, 2019 | 5.21 Mn |
| Mar 31, 2019 | 5.21 Mn |
| Dec 31, 2018 | 3.33 Mn |
| Dec 31, 2018 | 3.33 Mn |
| Sep 30, 2018 | -2.65 Mn |
| Sep 30, 2018 | -2.65 Mn |
| Jun 30, 2018 | -1.41 Mn |
| Jun 30, 2018 | -1.41 Mn |
| Mar 31, 2018 | -423,000.00 |
| Mar 31, 2018 | -423,000.00 |
| Mar 31, 2017 | -1.26 Mn |
| Mar 31, 2017 | -1.26 Mn |
| Dec 31, 2016 | 1.41 Mn |
| Dec 31, 2016 | 1.41 Mn |
| Sep 30, 2016 | 1.39 Mn |
| Sep 30, 2016 | 1.39 Mn |
| Mar 31, 2016 | -2.49 Mn |
| Mar 31, 2016 | -2.49 Mn |
| Dec 31, 2015 | -2.03 Mn |
| Dec 31, 2015 | -2.03 Mn |